Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 562,300 shares, a growth of 151.5% from the January 31st total of 223,600 shares. Based on an average daily volume of 3,240,000 shares, the days-to-cover ratio is currently 0.2 days.

Conduit Pharmaceuticals Price Performance

Shares of NASDAQ:CDT opened at $1.20 on Friday. The firm has a fifty day moving average price of $4.54 and a two-hundred day moving average price of $8.93. Conduit Pharmaceuticals has a one year low of $1.09 and a one year high of $392.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CDT. Rhumbline Advisers grew its stake in shares of Conduit Pharmaceuticals by 5,034.0% during the fourth quarter. Rhumbline Advisers now owns 1,028,702 shares of the company’s stock valued at $71,000 after buying an additional 1,008,665 shares during the last quarter. Citadel Advisors LLC boosted its holdings in Conduit Pharmaceuticals by 177.0% during the 4th quarter. Citadel Advisors LLC now owns 526,268 shares of the company’s stock valued at $36,000 after acquiring an additional 336,278 shares during the period. Geode Capital Management LLC boosted its holdings in Conduit Pharmaceuticals by 36.8% during the 4th quarter. Geode Capital Management LLC now owns 584,984 shares of the company’s stock valued at $40,000 after acquiring an additional 157,307 shares during the period. Finally, Barclays PLC grew its position in Conduit Pharmaceuticals by 6.5% during the 4th quarter. Barclays PLC now owns 892,350 shares of the company’s stock worth $61,000 after acquiring an additional 54,523 shares during the last quarter. Institutional investors own 3.29% of the company’s stock.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.